Over 600 Total Lots Up For Auction at Two Locations - CO 12/17, UT 12/18

Varredor de MRI/do mundo dos programas demostrativos de SiemensPET primeiro

por Barbara Kram, Editor | May 26, 2007
Siemens is first with
an MR-PET prototype

(click to enlarge)
In what could prove to be a turning point in diagnosis and therapy for millions of patients suffering from neurological diseases, stroke, and cancer, Siemens Medical Solutions showed results of a prototype for the world's first fully-functioning imaging system capable of simultaneously performing Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET). The first in-vivo human brain simultaneous MR-PET images were acquired in the Siemens facilities in the US. Testing of this new prototype MR-PET will start before the end of 2007.

MR-PET presents a tremendous leap forward in imaging capabilities. Siemens is the first company to have realized an MR-PET prototype, which brings the exceptional soft tissue contrast and high specificity of MR together with PET's excellent sensitivity in assessing physiological and metabolic states. The first MR-PET images were acquired with support of Dr. David Townsend and Dr. Claude Nahmias, both from the University of Tennessee, USA, and Dr. Heinz-Peter Schlemmer, Dr. Claus Claussen and Dr. Bernd Pichler, all from the University Tubingen in Germany. MR-PET has the potential to become the imaging modality of choice for neurological studies, certain forms of cancer, stroke, and the emerging study of stem cell therapy.

Unraveling the Mysteries of the Brain
Researchers expect that MR-PET will open new doors in understanding the pathologies and progression of various neurological disorders like Alzheimer's, Parkinson's, epilepsy, depression and schizophrenia. For example, PET can currently differentiate mild cognitive impairment from early-stage Alzheimer's, but cannot determine reduced brain volume caused by atrophy. By combining MR and PET, clinicians may be able to make a more sound determination of both cognitive impairment and atrophy. Furthermore, combining MR-PET and the new emerging neurological biomarkers has the great potential to strengthen the assessment of the condition.

Similarly, in stroke patients, the technology holds the promise of allowing physicians to study which brain tissues might be salvageable after a stroke. In other rehabilitation settings, such as for patients with traumatic brain injury, the Siemens MR-PET approach would improve care and workflow. In that case, patients would be only scanned once instead of having to go to two different locations and get two subsequent scans. "The ability to determine in great detail the loss of neurological function puts us on the path to better care," said Maerzendorfer.